LKFT Lakefront Biotherapeutics - American Depositary Shares
À propos de Lakefront Biotherapeutics - American Depositary Shares Présentation de l'entreprise depuis Wikipedia
Lakefront Biotherapeutics is a Belgian pharmaceutical research company which was founded in 1999. Its headquarters are located in Mechelen and has additional locations in Leiden, Romainville, Basel, Milan, Madrid, Boston and Zagreb.
Lire la suite
Lakefront Biotherapeutics (formerly known as Galapagos NV and Galapagos Genomics) is a Belgian pharmaceutical research company which was founded in 1999. Its headquarters are located in Mechelen and has additional locations in Leiden, Romainville, Basel, Milan, Madrid, Boston and Zagreb.
The company develops drugs against rheumatoid arthritis, Crohn's disease, ulcerative colitis, psoriasis, systemic lupus erythematosus and cystic fibrosis.
History
Galapagos Genomics NV was founded in 1999 as a joint venture between Crucell and Tibotec. The company later changed its name to Galapagos NV and completed its initial public offering on Euronext Amsterdam and Euronext Brussels in May 2005.
The company uses a technological platform for its research, which is based on adenoviruses to introduce human gene sequences into a wide variety of human cell lines to knock-in or knock-down specific proteins.
In 2019, Gilead Sciences and Galapagos entered into transformative research and development collaboration. Gilead and Galapagos have also agreed to amend certain terms around the development and commercialization of filgotinib.
In June 2022, the business announced it would acquire CellPoint for €125 million, with milestones of up to €100 million and AboundBio for $14million.
Effective April 1, 2022 Paul Stoffels replaced cofounder and CEO of 20 years Onno van de Stolpe.
In April 2026 the company was renamed to Lakefront Biotherapeutics.
Company
A German company, Galapagos Biopharma Germany GmbH, was established in 2019 and is headquartered in Munich, Germany. In December 2021, the company established an Austrian subsidiary, Galapagos Biopharma Austria GmbH, headquartered in Vienna, Austria.
Drugs
Filgotinib (GLPG0634) a selective inhibitor of JAK1 (Janus kinase 1) being developed for the treatment of rheumatoid arthritis and potentially Crohn's disease.
GLPG1205: a first-in-class GPR84-inhibitor currently under research for the treatment of inflammatory bowel disease.
Source : Wikipedia (Anglais), CC BY-SA 4.0 · Voir sur Wikipedia ↗
Pas encore de données fondamentales pour ce ticker.
Activistes et détenteurs de 5%+ 3 participations
Investisseurs ayant déposé un Schedule 13D auprès de la SEC — détention effective supérieure à 5% avec l'intention d'influencer l'émetteur (participations activistes, campagnes pour le conseil d'administration, fusions-acquisitions). Chaque ligne montre le dernier état connu de la position du déposant.
| Déclarant | Déposé | Participation | Statut | Objectif | Dépôt |
|---|---|---|---|---|---|
| EcoR1 Capital, LLC, Oleg Nodelman, EcoR1 Capital Fund Qualified, L.P., EcoR1 Capital Fund, L.P. ×4 dépôts | 28 juillet 2025 | 13,22% | Amendement | — | SEC |
| TANG CAPITAL MANAGEMENT, LLC, KEVIN TANG, TANG CAPITAL PARTNERS, LP, TANG CAPITAL PARTNERS INTERNATIONAL, LP, TANG CAPITAL PARTNERS III, INC, TANG CAPITAL PARTNERS IV, INC, CONCENTRA BIOSCIENCES, LLC | 14 février 2025 | 7,50% | Dépôt initial | Investissement passif | SEC |
| Van Herk Investments B.V., Van Herk Investments THI B.V., Van Herk Private Equity Investments B.V., Stichting Administratiekantoor Penulata, Van Herk Management Services B.V., Onroerend Goed Beheer – en Beleggingsmaatschappij A. van Herk B.V., A. van Herk Holding B.V., Stichting Administratiekantoor Abchrys, Adrianus van Herk | 2 novembre 2021 | — | Dépôt initial | Campagne de conseil d'administration | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Détention d'ETF Détenu par 18 ETFs
Le poids reflète uniquement les participations directes en actions (N-PORT) ; les fonds à effet de levier ou basés sur des dérivés peuvent détenir une exposition supplémentaire aux swaps non indiquée.
| Fonds | Poids | Unités | Au | Source |
|---|---|---|---|---|
| VXUS · VANGUARD STAR FUNDS | — | — | 15 juillet 2026 | Quotidien |
| VGK · VANGUARD INTERNATIONAL EQUITY INDEX… | — | — | 15 juillet 2026 | Quotidien |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | — | — | 15 juillet 2026 | Quotidien |
| VSS · VANGUARD INTERNATIONAL EQUITY INDEX… | — | — | 15 juillet 2026 | Quotidien |
| VEA · VANGUARD TAX-MANAGED FUNDS | — | — | 15 juillet 2026 | Quotidien |
| IBB · iShares Trust | — | — | 18 août 2026 | Quotidien |
| PDN · Invesco Exchange-Traded Fund Trust … | — | — | 13 juillet 2026 | Quotidien |
| VSGX · VANGUARD WORLD FUND | — | — | 30 juillet 2026 | Quotidien |
| EWK · iShares, Inc. | — | — | 20 juillet 2026 | Quotidien |
| IEUS · iShares Trust | — | — | 20 juillet 2026 | Quotidien |
| SCZ · iShares Trust | — | — | 18 août 2026 | Quotidien |
| IEFA · iShares Trust | — | — | 24 juillet 2026 | Quotidien |
| IXUS · iShares Trust | — | — | 17 août 2026 | Quotidien |
| IEUR · iShares Trust | — | — | 17 août 2026 | Quotidien |
| IDEV · iShares Trust | — | — | 22 juillet 2026 | Quotidien |
| WSML · iShares Trust | — | — | 20 juillet 2026 | Quotidien |
| IBBQ · Invesco Exchange-Traded Fund Trust … | — | — | 17 août 2026 | Quotidien |
| QQQS · Invesco Exchange-Traded Fund Trust … | — | — | 5 août 2026 | Quotidien |